FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Disclosed is a cancer treatment method consisting in introducing an effective quantity of durvalumab (MEDI4736) and an antisense compound aimed at STAT3 to a patient. Also disclosed is a set and a pharmaceutical composition for the treatment of cancer containing durvalumab and an antisense compound aimed at STAT3. Furthermore, the invention relates to a method for modulating infiltrating immune cells in a warm-blooded animal such as a human being, which involves introducing an effective quantity of durvalumab in front of an effective quantity of AZD9150, after said quantity or simultaneously with said effective quantity.
EFFECT: achieved is effective treatment of cancer.
22 cl, 1 tbl, 9 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
